PDCD1 and melanoma: In summary, we have demonstrated that a rational combination of two targeted therapy (BRAFi and anti‐mVEGFA) and an immunomodulatory agent (anti‐PD‐1) in melanoma can lead to a CR in a large fraction of mice bearing melanomas not responding to BRAFi/anti‐PD‐1 combination therapy.